Evaxion(EVAX)
Denmark - HørsholmBiotechnology
Focus: Evaxion is an AI-driven immunotherapy biotech founded in 2021, focused on personalized cancer vaccines using computational biology platforms. The company is publicly listed (NASDAQ: EVAX) and headquartered in Denmark.
Profile data last refreshed 21h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Open Jobs
1
Should You Work at Evaxion?
AI assessmentEvaxion is a high-risk, high-potential-upside play best suited to scientists who thrive on platform building and can tolerate extended pre-revenue stage with minimal near-term catalysts.
Why Work Here
- Early-stage platform company with AI/computational advantage in oncology immunotherapy, offering ground-floor opportunity to build proprietary technology
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
2 total
LOE Risk
Protected
No near-term cliffs
Hiring
1 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
EVX-02A
Melanoma Stage IVClinical Trials (1)
NCT04455503Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1
Phase 1/2Help build intelligence for Evaxion
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.